Cellectar Biosciences, Inc. hedge fund holdings
CLRB$1.78-0.09 (-4.81%)
Every quarter, large institutional investment managers with over $100M in U.S.-listed assets under management disclose their U.S. equity holdings through 13F filings. Read together, those filings show which businesses professional capital is moving into and out of.
Price vs funds buying and selling
Price vs funds buying and selling data
Showing the 1Y range: Oct 2, 2025 to Oct 2, 2026. Price (-69.3%). 0 fund reports plotted in this window as 0 markers; nearby trades of the same kind are grouped.
| Date | Category | Person | Role | Action | Amount | Change in holding |
|---|
Funds buying · new + increased
Funds selling · reduced + closed
Net buyers vs sellers
Price and fund activity data
| Quarter | Funds buying | Funds selling | Bought | Sold | Filers | Reported |
|---|---|---|---|---|---|---|
| Q2 2025 | 6 | 25 | $77.1K | $588K | 17 | Aug 14, 2025 |
| Q3 2025 | 10 | 4 | $1.11M | $17.9K | 20 | Nov 14, 2025 |
| Q4 2025 | 10 | 5 | $273K | $167K | 18 | Feb 14, 2026 |
| Q1 2026 | 3 | 6 | $79.3K | $180K | 18 | May 15, 2026 |
| Q2 2026 | 14 | 5 | $6.42M | $60.7K | 28 | Aug 14, 2026 |
Quarterly action breakdown
Q2 2026
New position
9$5.12M
Increased
5$1.3M
Reduced
1-$18.2K
Out / sold
4-$42.4K